Tamibarotene ( DrugBank: Tamibarotene )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 26 | HTLV-1関連脊髄症 | 1 |
| 96 | クローン病 | 1 |
26. HTLV-1関連脊髄症
臨床試験数 : 28 / 薬物数 : 48 - (DrugBank : 28) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01343355 (ClinicalTrials.gov) | January 2011 | 25/4/2011 | Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) | Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) | HTLV-I-Associated Myelopathy | Drug: Tamibarotene | St. Marianna University School of Medicine | NULL | Active, not recruiting | 30 Years | 75 Years | Both | 15 | Phase 2/Phase 3 | Japan |
96. クローン病
臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00417391 (ClinicalTrials.gov) | December 2006 | 28/12/2006 | Phase II Study of RR110 in Patients With Active Crohn's Disease | Phase II Study of RR110 in Patients With Active Crohn's Disease | Crohn's Disease | Drug: RR110 (Tamibarotene) | R&R Inc. | NULL | Completed | 20 Years | N/A | Both | 24 | Phase 2 | Japan |